^
Association details:
Biomarker:BCR-ABL1 fusion
Cancer:Chronic Myeloid Leukemia
Drug Class:Tyrosine kinase inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Title:

Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Excerpt:
A summary of recommendations is shown in Table 7...First-line management of chronic phase CML...TKI therapy should be commenced immediately after confirmation of BCR–ABL1 positivity. It is recommended to taper the hydroxyurea dose before its discontinuation.
DOI:
10.1093/annonc/mdx219